Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial, Lancet Oncol, vol.14, issue.2, pp.149-58, 2013. ,
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, vol.387, pp.1163-77, 2015. ,
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, vol.373, issue.8, pp.737-783, 2015. ,
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer, J Clin Oncol, vol.34, issue.14, pp.1652-1661, 2016. ,
Dissemination of prostatic carcinoma: an autopsy study, J Natl Med Assoc, vol.78, issue.11, pp.1083-1089, 1986. ,
Metastatic patterns of prostate cancer : an autopsy study of 1,589 patients, Hum Pathol, vol.31, issue.5, pp.578-83, 2000. ,
Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, vol.368, issue.2, p.30, 2012. ,
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5, J Clin Oncol, vol.33, issue.7, pp.723-754, 2015. ,
Enzalutamide in metastatic prostate cancer before chemotherapy, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.371, pp.178-211, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02169779
Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012. ,
Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, vol.364, issue.21, pp.1995-2005, 2011. ,
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res, vol.13, pp.6396-403, 2007. ,
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, vol.27, issue.3, pp.454-60, 2015. ,
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes -31 -from the randomized controlled phase 3 AFFIRM trial. Cancer, vol.123, pp.253-262, 2016. ,
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients, J Clin Oncol, vol.30, 2012. ,
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 2003. ,
, Apr, vol.1, issue.7, pp.1232-1239
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, vol.105, issue.22, pp.1729-1766, 2013. ,
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, vol.65, issue.1, pp.3-6, 2013. ,
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castrationresistant prostate cancer, J Clin Oncol, vol.32, issue.7, pp.671-678, 2014. ,
Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel, Eur J Cancer, vol.50, issue.9, pp.1617-1644, 2014. ,
, ESMO Consensus Conference Guidelines, vol.24, p.32, 2009.
, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, pp.178-211, 2017.
, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, pp.178-211, 2017.
, ESMO Consensus Conference Guidelines, vol.24, pp.1141-62, 2009.
Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel, Eur J Cancer, vol.50, issue.9, p.37, 2014. ,
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial, Lancet Oncol, vol.14, issue.2, pp.149-58, 2013. ,
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, vol.387, pp.1163-77, 2015. ,
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, vol.373, issue.8, pp.737-783, 2015. ,
Dissemination of prostatic carcinoma: an autopsy study, J Natl Med Assoc, vol.78, issue.11, pp.1083-1089, 1986. ,
Metastatic patterns of prostate cancer : an autopsy study of 1,589 patients, Hum Pathol, vol.31, issue.5, pp.578-83, 2000. ,
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res, vol.13, pp.6396-403, 2007. ,
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, vol.27, issue.3, pp.454-60, 2015. ,
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer, vol.123, pp.253-262, 2016. ,
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients, J Clin Oncol, vol.30, 2012. ,
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer, p.38 ,
, J Clin Oncol, vol.34, issue.14, pp.1652-1661, 2016.
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, vol.21, issue.7, pp.1232-1239, 2003. ,
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, vol.105, issue.22, pp.1729-1766, 2013. ,
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, vol.65, issue.1, pp.3-6, 2013. ,
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castrationresistant prostate cancer, J Clin Oncol, vol.32, issue.7, pp.671-678, 2014. ,
Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, vol.368, issue.2, pp.138-186, 2012. ,
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5, J Clin Oncol, vol.33, issue.7, pp.723-754, 2015. ,
Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012. ,
Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, vol.364, issue.21, pp.1995-2005, 2011. ,
Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, vol.371, issue.18, pp.1755-1761, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02169779